# As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations

> **NCT00796185** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 62 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Paliperidone ER

## Key facts

- **NCT ID:** NCT00796185
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2004-01
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796185, "As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00796185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*